Edinburgh cell-therapy company awarded £7.25m grant
RoslinCT, a global cell-therapy contract development and manufacturing organisation (CDMO), has announced it has been awarded a £7.25m R&D grant from Scottish Enterprise, to accelerate the digital transformation of its manufacturing operations in Scotland.
The funding forms part of RoslinCT’s digital-expansion plan, a multi-year initiative designed to enhance the company’s integrated digital and AI capabilities and further strengthen Scotland’s position as a global hub for advanced cell and gene-therapy manufacturing.
The programme will enable the development of a digitally integrated manufacturing environment, improving operational efficiency, data connectivity and manufacturing excellence across RoslinCT’s operations.
The firm said that by creating a more connected and data-driven manufacturing environment, it will be better positioned to support clients throughout the product lifecycle, helping bring innovative cell therapies to patients faster and more cost-effectively.
Peter Coleman, chief executive officer of RoslinCT, said: “This support from Scottish Enterprise represents an important investment in the future of advanced therapy manufacturing in Scotland. Digital technologies are transforming how cell therapies are developed and manufactured, enabling greater efficiency, consistency and scalability while maintaining the highest quality standards.
“At RoslinCT, we are committed to building world-class manufacturing capabilities that help our clients bring innovative therapies to patients faster. This programme will strengthen our digital infrastructure, support continued innovation and reinforce Scotland’s position as a leading destination for cell and gene therapy manufacturing.”
The programme forms part of RoslinCT’s long-term strategy to invest in advanced manufacturing technologies and create a highly connected, digitally enabled manufacturing environment that supports both clinical and commercial cell-therapy production. The project is also expected to contribute significantly to Scotland’s life-sciences sector through job creation and long-term economic growth.
RoslinCT has 22 purpose-built cell-therapy suites across sites in Edinburgh and Hopkinton, Massachusetts in the US.
Founded in 2005 and built on the scientific heritage of the Roslin Institute – home of the groundbreaking cloning of Dolly the Sheep – RoslinCT has played a pivotal role in advancing innovative cell-based medicines from early development through commercialisation, with manufacture of commercial products at both sites.
Pictured: Peter Coleman, RoslinCT chief executive
Comments